HR-8339-119
Referred to the House Committee on Energy and Commerce.
Sponsored by Doris Matsui (D-CA)
What it does
This bill would require drug manufacturers to report more detailed information to the FDA about their supply chains, including the identity of suppliers of active pharmaceutical ingredients and the amounts of drug produced using ingredients from each supplier, with reports submitted up to four times a year instead of annually. It would also require drug and active pharmaceutical ingredient labels or certificates of analysis to identify the original manufacturer's name, location, and unique facility identifier, with the FDA allowed to permit reasonable variations in how this is implemented.
Who benefits
Patients and healthcare providers who would gain more visibility into where drugs and their ingredients originate, particularly amid concerns about reliance on foreign API suppliers in countries like China and India. Domestic pharmaceutical manufacturers with transparent, U.S.-based supply chains may gain a competitive or marketing advantage. Public health officials and regulators tracking drug shortages or contamination risks would gain more granular data.
Who is hurt
Generic drug manufacturers and API suppliers, especially smaller or foreign-based firms, would bear increased compliance and reporting costs, potentially raising production costs. Companies relying on complex multi-supplier ingredient sourcing may face administrative burdens from quarterly reporting and relabeling requirements. Some of these costs could be passed through to distributors, pharmacies, or ultimately consumers via drug prices.
Supporters argue
Supporters argue that the United States has become dangerously dependent on foreign, often opaque, sources for active pharmaceutical ingredients, and that recent shortages and contamination incidents (such as tainted generic drugs) show regulators and the public lack basic visibility into where medicines actually come from. They contend that more frequent reporting and clear labeling would help the FDA detect supply chain vulnerabilities and quality risks before they cause harm.
Opponents argue
Opponents argue that quarterly reporting requirements and new labeling mandates would impose significant compliance costs on manufacturers, particularly smaller generic drug makers operating on thin margins, potentially discouraging market entry and worsening existing generic drug shortages. They contend that the FDA's broad discretion to specify additional required information via guidance, rather than formal rulemaking, could impose shifting obligations on industry without adequate procedural safeguards.
Constitutional context
Congress regulates drug manufacturing and interstate distribution under the Commerce Clause (Art. I, §8, cl. 3), and the bill's delegation of authority to the Secretary of Health and Human Services to specify reporting content and labeling variations through regulation or guidance will be subject to independent judicial review of statutory authorization under Loper Bright Enterprises v. Raimondo (2024) rather than automatic deference.
Checks and balances
Congress expands the FDA's regulatory and information-gathering authority over drug manufacturers, while courts retain the power to review whether specific FDA guidance or regulations exceed the statutory authorization Congress provided.
Historical precedent
The Drug Supply Chain Security Act of 2013 similarly expanded FDA tracking and reporting requirements for pharmaceutical distribution to address supply chain integrity concerns.